Nikolaos A. Dallas, Vice President and Clinical Lead, Cancer National Service Line, IL Division at Advocate Health, shared on LinkedIn:
“For pancreatic cancer, progress has historically come far too slowly. Today, there is real reason for hope.
On World Pancreatic Cancer Day, one of the developments that stands out to me is the Phase 3 RASolute 302 trial. Daraxonrasib nearly doubled median overall survival, from 6.7 months with chemotherapy to 13.2 months, in previously treated metastatic pancreatic cancer.
Think about what that represents. A disease overwhelmingly driven by RAS alterations, a target once considered ‘undruggable,’ is entering a new era of targeted therapy.
At Advocate Health, this is why we continue to focus on connecting patients with multidisciplinary expertise, innovation, and clinical trials across the cancer journey.
We have much more work to do. But today, there is genuine reason for optimism.
Research changes possibilities. And possibilities change lives.”
You can also read: New Daraxonrasib Combination Shows 60.7% Response Rate in Pancreatic Cancer
